<DOC>
	<DOC>NCT00715689</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NNC126-0083 in growth hormone deficient adults</brief_summary>
	<brief_title>Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>GHDA subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II Fertile females must agree to use appropriate contraceptive methods and have a negative pregnancy test at inclusion GH replacement therapy for more than 3 months Body Mass Index (BMI, kg/m2) of 22.0 to 35.0 kg/m2, both inclusive Females of childbearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using adequate contraceptive methods Malignant disease Proliferative retinopathy judged by retinaphoto within the last year only with concomitant diabetes Heart insufficiency, NYHA class greater than 2 Subjects with diabetes with an HbA1C above 8.0% Diabetic receiving insulin treatment Stable pituitary replacement therapy for less than 3 months Impaired liver function Impaired kidney function</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>